1880 Century Park East, Suite #315
15 articles with BriaCell
8/13/2018GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those!
BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site.
The company's CRO will manage the clinical and regulatory aspects of the clinical trial on behalf of BriaCell.
The company is pleased to provide a further update on its ongoing clinical trial of Bria-IM.
BriaCell is providing a clinical update regarding its ongoing clinical trials of Bria-IMT.
The company disclosed the allowance by the USPTO and also the EPO of two patent applications related to protein kinase C delta (PKCδ) inhibitor technology,
The Phase I/IIa study evaluates the safety and activity of BriaVax in patients with advanced breast cancer. To boost the anti-tumor effects of BriaVax.
FDA Approves BriaCell's Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients With Advanced Breast Cancer
The study allows the patients who did not respond to BriaVax to be treated in combination with either pembrolizumab or ipilimumab.
BriaCell Adds Third Clinical Site – Led By Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial In Advanced Breast Cancer
BriaCell Provides Clinical Update On Its Ongoing Phase I/IIa Clinical Study Of BriaVax In Advanced Breast Cancer